Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

►Glucocorticoid osteoporosis (GIO) is common but whether there are gender differences in response to therapy is unknown. ►Examined benefits of zoledronate and risedronate in male patients with GIO. ►Single zoledronate infusion superior to risedronate in effects on BMD at most skeletal sites and bone turnover. ►Effect seen in both prevention and treatments arms.